

National Board of Examinations

Question Paper Name :	DrNB GYNAECOLOGICAL ONCOLOGY Paper2
Subject Name :	DrNB GYNAECOLOGICAL ONCOLOGY Paper2
Creation Date :	2022-06-25 17:19:47
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DrNB GYNAECOLOGICAL ONCOLOGY Paper2

Group Number :	1
Group Id :	3271871273
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Break time :	0
Group Marks :	100
Is this Group for Examiner? :	No
Examiner permission :	Cant View
Show Progress Bar? :	No

DrNB GYNAECOLOGICAL ONCOLOGY Paper2

Section Id :	3271871276
---------------------	------------

Section Number : 1
Section type : Offline
Mandatory or Optional : Mandatory
Number of Questions to be attempted : 10
Section Marks : 100
Enable Mark as Answered Mark for Review and Clear Response : Yes
Maximum Instruction Time : 0
Sub-Section Number : 1
Sub-Section Id : 3271871280
Question Shuffling Allowed : No

Question Number : 1 Question Id : 32718711782 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. Minimally invasive surgery in cervical cancer:

- a) LACC trial- survival, peri-operative complication and Quality of life outcomes. [6]
- b) Briefly describe ongoing trials on MIS in cervical cancer. [4]

Question Number : 2 Question Id : 32718711783 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Sentinel lymph node (SLN) biopsy in Endometrial cancer:

- a) Various techniques and their diagnostic performances. [4]
- b) Ultra-staging of SLN. [3]

c) Management of SLN positive patient. [3]

Question Number : 3 Question Id : 32718711784 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Immunotherapy:

a) Basis of cancer immunotherapy. [3]

b) Role in endometrial cancer. [4]

c) Enumerate common toxicities. [3]

Question Number : 4 Question Id : 32718711785 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Uterine sarcomas:

a) FIGO staging. [3]

b) Role of oophorectomy, and lymph node dissection. [3]

c) Indications for adjuvant radiation and/ or systemic therapy in frontline management. [4]

Question Number : 5 Question Id : 32718711786 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Management of recurrent ovarian cancer:

a) Selection of patients for secondary cytoreductive surgery. [5]

b) Role of Poly adenosine diphosphate-ribose polymerase inhibitors (PARPi). [5]

Question Number : 6 Question Id : 32718711787 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

HIPEC in ovarian cancer:

a) Critically evaluate evidence for HIPEC in advanced ovarian cancer. [5]

b) Briefly describe peri-operative complications of HIPEC and their management. [5]

Question Number : 7 Question Id : 32718711788 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Briefly describe clinical features and management of :

- a) Ultra high risk *Gestational trophoblastic* neoplasia (GTN). [5]
- b) Placental site trophoblastic tumour (PSTT). [5]

Question Number : 8 Question Id : 32718711789 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

- a) Describe risk reducing surgeries in women with cancer gene mutation carriers. [7]
- b) SEE- FIM protocol. [3]

Question Number : 9 Question Id : 32718711790 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

- a) Enumerate peri-operative complications of radical hysterectomy and lymphadenectomy. [5]
- b) How will you approach a patient who presents with copious watery discharge per vaginum on 9th post-operative day after radical hysterectomy? [5]

Question Number : 10 Question Id : 32718711791 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

FIGO Staging for cervical cancer:

- a) Describe updated FIGO staging with rationale for revision recommendations. [6]
- b) What are shortcomings of revised staging system. [4]

